Background: In blood vessels 5-HT stimulates sympathetic nerves, the endothelium and vascular smooth muscle cells. Triptans are specific anti-migraine drugs and they activate the serotoninergic 5HT1b/d receptors causing vasoconstriction of the cerebral vessels.
Aim: To evaluate the effect of frovatriptan on isolated rat carotid artery.
Methods: Contractile activity of the preparations was registered isometrically. Krebs solution (pH = 7.4) was used for washing smooth muscle (SM) preparations aerated with 95% O2 and 5% CO2 at 37°C. The 60-minute adaptation of tone level of preparations was taken as a starting tone and the changes such as contraction or relaxation were calculated using it.
Results: Frovatriptan (1×10-6 mol/l - 1×10-5 mol/l) induced a contraction, but at higher concentrations it caused relaxation of the carotid artery. The L-norepinephrine contractile reaction was enhanced in the presence of frovatriptan. In the presence of 5-HT2 receptor antagonist, methysergide, frovatriptan increased the relaxation. In the presence of the specific α-1 receptor antagonist, prazosin, the frovatriptan-induced relaxation decreased.
Conclusion: The observed contractile effect of frovatriptan is probably associated with the main effect of the drug - activation of the serotoninergic 5HT1B /1D receptors causing vasoconstriction of the cerebral vessels and their anti-migraine effect. At higher concentrations, frovatriptan, most likely via some non-specific mechanism, could activate the following intracellular chain reaction: stimulation of α1D could activate eNOS which may increase in the concentration of NO which results in the final effect of relaxation.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Kaumann JA, Levy FO. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 2006;111(3):674-706.
2. Geerts IS, Matthys KE, Herman AG, et al. Involvement of 5-HT1B receptors in collar-induced hypersensitivity to 5-hydroxytryptamine of the rabbit carotid artery. Br J Pharmacol 1999;127(6):1327-36.
3. Roberto G, Piccinni C, D’Alessandro R, et al. Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database. Cephalalgia 2014;34(1):5-13.
4. Tullo V, Valguarnera F, Barbanti P, et al. Comparison of frovatriptan plus dexketoprofen (25mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: A randomized study. Cephalalgia 2014;34(6):434-45.
5. Savi L, Mogavero S, Egan CG. Effi cacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. Drug Des Devel Ther 2014;8:983-92.
6. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem 1948;176(3):1243-51.
7. Erspamer V, Asero B. Identifi cation of enteramine, the specifi c hormone of the enterochromaffi n cell system, as 5-hydroxytryptamine. Nature 1952;169 (4306):800-1.
8. Page IH, McCubbin JW. Modifi cation of vascular response to serotonin by drugs. Am J Physiol 1953;174(3):436-44.
9. Goadsby PJ. Serotonin 5-HT1B/1D receptor agonists in migraine comparative pharmacology and its therapeutic implications. CNS Drugs 1998;10(4):271-86.
10. Willems EW, Heiligers JPC, De Vries P, et al. Alpha1- adrenoceptor subtypes mediating vasoconstriction in the carotid circulation of anaesthetized pigs: possible avenues for antimigraine drug development. Cephalalgia 2001;21:110-9.
11. McCune DF, Edelmann SE, Olges JR, et al. Regulation of the cellular localization and signaling properties of the alpha(1B)- and alpha(1D)-adrenoceptors by agonists and inverse agonists. Mol Pharmacol 2000;57(4):659-66.
12. Zschauer AO, Sielczak MW, Smith DA, et al. Norepinephrine- induced contraction of isolated rabbit bronchial artery: role of alpha 1- and alpha 2-adrenoceptor activation. J Appl Physiol 1997;82(6):1918-25.
13. de Andrade CR, Fukada SY, Olivon VC, et al. Alpha1 D-adrenoceptor-induced relaxation on rat carotid artery is impaired during the endothelial dysfunction evoked in the early stages of hyperhomocysteinemia. Eur J Pharmacol 2006;543(1-3):83-91.
14. Lee MR, Li L, Kitazawa T. Cyclic GMP causes Ca2+ desensitization in vascular smooth muscle by activating the myosin light chain phosphatase. J Biol Chem 1997;272(8):5063-8.
15. Carvajal JA, Germain AM, Huidobro-Toro JP, et al. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol 2000;184(3):409-20.
16. Lowry JL, Brovkovych V, Zhang Y, et al. Endothelial nitric-oxide synthase activation generates an inducible nitric-oxide synthase-like output of nitric oxide in infl amed endothelium. J Biol Chem 2013;288(6):4174-93.